Near future
Contact us
  • Home
  • Tech
  • Health
  • Environment
  • Architecture
  • energia
  • Transportation
  • Spazio
  • AI
  • concepts
  • Gadgets
  • Italy Next
  • H+
July 2 2022

Coronavirus / Russia-Ukraine

Near future

News to understand, anticipate, improve the future.

No Result
View All Result

News to understand, anticipate, improve the future.

Read in:  Chinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

Update: the anti-obesity drug works wonders, but must be taken for life

It has shown surprising results and now the demand is very high: but to bring down obesity it forces a life of drugs. What do you think?

Gianluca Ricciodi Gianluca Riccio
in Medicine
Share107Pin25Tweet67SendShare19ShareShare13
wegovy anti obesity
May 25, 2022
⚪ Reads in 4 minutes
A A

Domenica Rubino directs the Washington Center for Weight Management and Research in Arlington, Virginia and helps people lose weight. Not all, however. For her admission of her, there are a bunch of patients literally crushed by obesity, which until yesterday she was unable to help in any way.

People who, while trying all kinds of diets, exercises, surgeries always end up regaining weight. Some have problems related to severe obesity, such as diabetes, hypertension, arthritis.

Recently, all these people have hope again. There is a new class of obesity drugs that is hitting the mark, because it acts directly on the brain-gut axis that regulates appetite.

Maybe you are also interested

The gym in pills is near: news from the molecule of physical exercise

Protein destroys difficult tumors: it can lead to a "universal" cure

Alopecia, a new US drug treats 40% of patients: the FDA asked for ok

Tirzepatide, remarkable tests: average weight loss of 24kg. Goodbye obesity?

Wegovy against obesity: it works ...

"We are finally able to help people who suffer the greatest complications of obesity lose weight," says Ruby.

Of the drug that makes everyone cry for a miracle, semaglutide, I spoke to you six months ago. Has been approved in June 2021 under the name “Wegovy” for the treatment of people with a BMI in the obesity range or just below, but with weight-related health problems. 

Uno study published last year on New England Journal of Medicine found that, on average, those who took semaglutide lost 14,9% of its initial body weight compared to 2,4% of the placebo group. 

They were exceptional results, double those obtained from previous anti-obesity drugs. Weight reduction is accompanied by benefits in blood pressure, blood sugar and saturated fat.

obesity

… But it has a big drawback

Robert Kushner from Northwestern University, one of the study's lead researchers, points out that the drug is a new paradigm for the hormone treatment of obesity. 

Why hormonal? Because it "mimics" an intestinal hormone called GLP-1 (glucagon-like peptide-1) which acts on three fronts. On the pancreas increases insulin production. On the stomach to slow down emptying. On the brain to reduce appetite and signal satiety. Patients eat less and are not bothered by hunger, real or "nervous". 

The drawback is one, but it is significant: these drugs must be used for life, just like those for diabetes, otherwise the benefits are lost. A 2021 study conducted by Rubino herself shows patients gain weight if they stop taking the drug. 

This can also make us understand that severe obesity is not a transient condition linked mainly to behavioral and environmental factors, as many see it. Rather, according to several studies, it is a chronic and relapsing disease, which disrupts multiple physiological systems.

wegovy obesity
Senza titolo

Important doubts

The prospect of a lifetime of weekly injections to maintain weight loss raises many questions, especially about safety: anything that alters fundamental functions such as metabolism and energy balance can have significant side effects. 

Of course, in the drug study it was found that only 4,5% of treated patients experienced gastrointestinal syndromes, and researchers say that taken at a low dose this drug has a good safety profile. The dose to be taken to lose weight, however, is greater: and taken for decades it could present problems as yet unknown.

Another problem? Without a doubt the cost. We are talking about over 1300 euros per month: the demand is very high, but in countries with private healthcare it is practically a nightmare. As if to say: obesity is the cause of many evils, but it is also a consequence.

tags: drugsobesity
Previous post

Floating turbines: the strongest tidal flows in the world “tamed” to give energy

Next Post

New study: electric batteries could last 100 years

COLLABORATE

To submit articles, disclose the results of a research or scientific discoveries write to the editorial staff

    archive

    Have a look here:

    A meteor brightly illuminates the skies over northeastern China
    Spazio

    A meteor brightly illuminates the skies over northeastern China

    Numerous surveillance videos show a fireball falling from the skies of northeast China. The meteor is still ...

    Read More
    china center

    How much is China running: chronicle of its return to the Center

    Electric vehicle emergency: the entire energy network must be designed

    Electric vehicle emergency: the entire energy network must be designed

    Digital health, here are the trends that will boom (or flop) in 2021

    Digital health, here are the trends that will boom (or flop) in 2021

    SpaceX, on Mars in 2018

    SpaceX, on Mars in 2018

    The daily tomorrow

    Futuroprossimo.it provides news on the future of technology, science and innovation: if there is something that is about to arrive, here it has already arrived. FuturoProssimo is part of the network ForwardTo, studies and skills for future scenarios.

    Subscribe to our newsletter

    Environment
    Architecture
    Artificial intelligence
    Gadgets
    concepts
    Design

    Staff
    Archives
    Advertising
    Privacy Policy

    Medicine
    Spazio
    Robotica
    Work
    Transportation
    energia

    To contact the FuturoProssimo editorial team, write to [email protected]

    Chinese Version
    Édition Française
    Deutsche Ausgabe
    Japanese version
    English Edition
    Edição Portuguesa
    Русское издание
    Spanish edition

    This work is distributed under license Creative Commons Attribution 4.0 International.
    © 2021 Futuroprossimo

    No Result
    View All Result
    • Home
    • Tech
    • Health
    • Environment
    • Architecture
    • energia
    • Transportation
    • Spazio
    • AI
    • concepts
    • Gadgets
    • Italy Next
    • H+